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Abstract
Background: Advanced glycation end products (AGEs), senescent macroprotein derivatives formed during a
normal aging process and acceleratedly under diabetic conditions, play a role in atherosclerotic cardiovascular
disease. AGEs cause endothelial cell (EC) damage, an initial trigger for atherosclerosis through the interaction with
a receptor for AGEs (RAGE). We have previously shown that n-butanol extracts of Morinda citrifolia (noni), a plant
belonging to the family Rubiaceae, block the binding of AGEs to RAGE in vitro. In this study, we examined the
effects of n-butanol extracts of noni on reactive oxygen species (ROS) generation and inflammatory reactions on
AGE-exposed human umbilical vein ECs (HUVECs).
Methods: HUVECs were treated with 100 μg/ml AGE-bovine serum albumin (AGE-BSA) or non-glycated BSA in
the presence or absence of 670 ng/ml n-butanol extracts of noni for 4 h. Then ROS generation and inflammatory
and gene expression in HUVECs were evaluated by dihydroethidium staining and real-time reverse transcription-polymerase
chain reaction analyses, respectively. THP-1 cell adhesion to HUVECs was measured after 2-day incubation of AGE-BSA or
BSA in the presence or absence of 670 ng/ml n-butanol extracts of noni.
Results: N-butanol extracts of noni at 670 ng/ml significantly inhibited the AGE-induced ROS generation and RAGE,
intercellular adhesion molecule-1 and plasminogen activator inhibitor-1 gene expressions in HUVECs. AGEs significantly
increased monocytic THP-1 cell adhesion to HUVECs, which was also prevented by 670 ng/ml n-butanol extracts of noni.
Conclusions: The present study demonstrated for the first time that N-butanol extracts of noni could suppress the
AGE-induced inflammatory reactions in HUVECs through its anti-oxidative properties via blocking of the interaction of
AGEs with RAGE. Inhibition of the AGE-RAGE axis by n-butanol extracts of noni may be a novel nutraceutical strategy for
the treatment of cardiovascular disease.
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Background
Reactive derivatives from non-enzymatic reactions
between sugars and amino groups of proteins, lipids and
nucleic acids form a heterogeneous group of irreversible
adducts called “AGEs (advanced glycation end prod-
ucts)” [1–3]. The formation and accumulation of AGEs
have been known to progress at a physiological normal
aging process and more acceleratedly under diabetic
conditions, thereby being involved in the development
and progression of atherosclerotic cardiovascular disease
[1–14]. Indeed, diabetic apolipoprotein E-deficient mice
fed an AGE-restricted diet exhibited less atherosclerotic
lesions, which were associated with decreased AGEs,
receptor for AGEs (RAGE) and inflammatory cells in the
aortic roots [5]. There was a correlation between AGE
levels and the degree of atheroma in cholesterol-fed rab-
bits, whereas treatment with aminoguanidine, an inhibi-
tor of AGE formation decreased plaque formation in the
aortae of these animals [6]. Administration of a recom-
binant soluble form of RAGE consisting of the extracel-
lular AGE-binding domain, has not only suppressed the
development of atherosclerosis but also stabilized estab-
lished atherosclerosis in diabetic apolipoprotein E-null
mice [7, 8]. RAGE-deficient mice were found to be
resistant to the development of atherosclerosis when
they were rendered diabetic [9]. Furthermore, circulating
levels of AGEs have also been shown to predict total and
cardiovascular disease mortality in both type 1 and type
2 diabetic patients [10, 11]. These observations suggest
that the inhibition of the AGE-RAGE axis is a novel
therapeutic target for atherosclerotic cardiovascular
disease, espeicially in elderly people or diabetic patients.
We have previously shown that n-butanol extracts of
Morinda citrifolia (noni), a plant belonging to the family
Rubiaceae, which has been used for centuries by Pacific
Islanders as an alternative medicine for various disor-
ders, such as diabetes and arthritis [15, 16], block the
binding of AGEs to RAGE in vitro [17]. In this study, we
examined the effects of n-butanol extracts of noni on
reactive oxygen species (ROS) generation and inflamma-




Bovine serum albumin (BSA) (essentially fatty acid free
and essentially globulin free, lyophilized powder) and
D-glyceraldehyde were purchased from Sigma (St. Louis,
MO, USA). Ethyl acetate and n-butanol were purchased
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).
Preparation of AGE-BSA
AGE-modified BSA was prepared as described previ-
ously [18]. In brief, BSA (25 mg/ml) was incubated
under sterile conditions with 0.1 M glyceraldehyde in
0.2 M NaPO4 buffer (pH 7.4) at 37 °C for 7 days.
Control non-glycated BSA was incubated in the same
conditions except for the absence of glyceraldehyde as
described previously [18].
Cells
HUVECs obtained from Lonza Group Ltd. (Basel,
Switzerland) were cultured in endothelial basal medium
supplemented with 2% fetal bovine serum, 0.4% bovine
brain extracts, 10 ng/ml human epidermal growth factor
and 1 μg/ml hydrocortisone according to the manufac-
turer’s recommendation. AGE or non-glycated BSA
treatment was carried out in a medium lacking epider-
mal growth factor and hydrocortisone. Cells at passage
4–11 were used for the present experiments. According
to the certificate of analysis by Lonza Group Ltd.,
HUVECs were pooled from Caucasian newborn babies.
Isolated cells were identified as HUVECs because cells
expressed CD31/105, von Williebrand Factor VIII, and
were positive for acetyated low-density lipoprotein
uptake. All cells were negative for mycoplasma.
Preparation of n-butanol extracts of noni
Morinda citrifolia fruits were collected in French
Polynesia during 2004–2006 and identified by botanists
at Tropical Resources, Inc. (Provo, UT, USA) where
voucher specimens were deposited (Part No. 119107,
Lot Code 52488, Batch # 23401). The fruits were sepa-
rated into flesh and seeds by hand. The flesh was freeze-
dried, extracted with 50% ethanol, and then the extracts
were further extracted with ethyl acetate and n-butanol
several times as described previously [19].
Dihydroethidium (DHE) staining
HUVECs were treated with 100 μg/ml AGE-BSA or non-
glycated BSA in the presence or absence of 670 ng/ml
n-butanol extracts of noni for 4 h. Then the cells were
incubated with phenol red free Dulbecco's Modified Eagle
Medium containing 3 μM DHE (Molecular Probes Inc.,
Eugene, OR, USA). After 15 min, ROS generation was eval-
uated by intensity of DHE staining as described previously
[20]. Intensity of DHE staining in five different field of each
sample was analyzed by microcomputer-assisted image J.
Real-time reverse transcription-polymerase chain reactions
(RT-PCR)
HUVECs were treated with 100 μg/ml AGE-BSA or
non-glycated BSA in the presence or absence of 670 ng/
ml n-butanol extracts of noni for 4 h. Then total RNA
was extracted with RNAqueous-4PCR kit, and quantita-
tive real-time RT-PCR was performed using Assay-on-
Demand and TaqMan 5 fluorogenic nuclease chemistry
(Applied Biosystems, Foster city, CA, USA) as described
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previously [20]. IDs of primers for human RAGE, inter-
cellular adhesion molecule-1 (ICAM-1), plasminogen
activator inhibitor-1 (PAI-1), β-actin, and 18S gene were
Hs00542592_g1, Hs00164932_m1, Hs01126606_m1, Hs0
1060665_g1, and Hs03003631_g1, respectively.
Assay of THP-1 cell adhesion to HUVECs
Human THP-1 monocytic leukemia cells were
purchased from American Type Culture Collection
(Manassas, VA, USA) and labeled with 3 μM BCECF-
AM (Dojindo, Kumamoto, Japan) as described previ-
ously [21]. HUVECs were treated with 100 μg/ml
AGE-BSA or non-glycated BSA in the presence or
absence of 670 ng/ml n-butanol extracts of noni for 24 h
and then incubated with BCECF-AM-labeled THP-1
cells for 4 h. After the incubation, non-adherent THP-1
cells were removed, and fluorescent intensities of the
adherent THP-1 cells were measured as described previ-
ously [21].
Statistical analysis
All values were presented as mean ± standard error.
One-way ANOVA followed by Student’s t-test was per-
formed for statistical comparisons; p < 0.05 was consid-
ered significant. All statistical analyses were performed
using the R version 3.2.5 (Copenhagen Business School,
Frederiksberg, Denmark).
Results
Effects of noni extracts on ROS generation
We first examined the effects of n-butanol extracts of
noni on ROS generation in HUVECs. As shown in Fig. 1,
AGEs significantly increased ROS generation in
HUVECs, which was prevented by 670 ng/ml n-butanol
extracts of noni. Noni extracts did not affect ROS gener-
ation in non-glycated BSA-exposed HUVECs.
Effects of noni extracts on RAGE, ICAM-1 and PAI-1 gene
expressions
We next investigated the effects of noni extracts on inflam-
matory reactions in HUVECs. AGEs up-regulated RAGE
mRNA levels in HUVECs, which was associated with the in-
creases in ICAM-1 and PAI-1 gene expressions (Fig. 2).
N-butanol extracts of noni at 670 ng/ml significantly blocked
the AGE-induced gene expressions of RAGE, ICAM-1 and
PAI-1 in HUVECs. Noni extracts did not affect these mRNA
levels in non-glycated BSA-exposed HUVECs.
Effects of noni extracts on THP-1 cell adhesion to HUVECs
We further studied the effects of noni extracts on THP-1
cell adhesion to HUVECs. As shown in Fig. 3, 670 ng/ml
n-butanol extracts of noni significantly prevented the
increase in THP-1 cell adhesion to AGE-exposed
HUVECs. Noni extracts did not affect THP-1 cell adhe-
sion to non-glycated BSA-exposed HUVECs.
Fig. 1 Effects of noni extracts on ROS generation in AGE-exposed HUVECs. HUVECs were treated with 100 μg/ml AGE-BSA or non-glycated BSA in
the presence or absence of 670 ng/ml n-butanol extracts of noni for 4 h. Then superoxide generation was evaluated by intensity of DHE staining.
Upper panels show the representative photos of DHE stainings. Lower panel shows the quantitative data. N = 3 per group. *, p < 0.05 compared to
the value with AGEs alone
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Discussion
There is an accumulating body of experimental and epi-
demiological evidence that atherosclerosis is intrinsically
an inflammatory disease and that endothelial cell dam-
age and dysfunction are an initial event that leads to the
development of atherosclerotic cardiovascular disease
[22–24]. Furthermore, recent understandings of the dis-
ease process have also revealed that AGEs and RAGE
interaction could evoke oxidative stress generation and
cause inflammatory reactions, thus contributing to the
increased risk for cardiovascular disease in elderly
patients, especially poorly controlled diabetes [4–9, 25,
26]. We have very recently found that n-butanol extracts
of noni could prevent the interaction of AGEs with
RAGE in vitro by binding RAGE with a dissociation
constant of 640 μg/ml and a half maximal inhibitory
concentration of 200 ng/ml [17]. Therefore, we exam-
ined here the effects of n-butanol extracts of noni on the
AGE-RAGE axis in HUVECs.
In this study, we found for the first time that n-buta-
nol extracts of noni significantly inhibited the AGE-
induced ROS generation, RAGE, ICAM-1 and PAI-1
gene expressions in HUVECs, which were associated
with attenuation of THP-1 cell adhesion to AGE-ex-
posed HUVECs. We have previously shown that anti-
body or antisense DNA raised against RAGE completely
inhibits the AGE-evoked ROS generation in endothelial
cells, while an anti-oxidant N-acetylcysteine or RAGE anti-
body itself blocks up-regulation of RAGE mRNA levels in
AGE-exposed endothelial cells [21, 27, 28]. So our present
study suggests that n-butanol extracts of noni may inhibit
the deleterious effects of AGEs by breaking the vicious
cycle between ROS generation and RAGE overexpression
in HUVECs.
ICAM-1 stimulates the recruitment and firm adhesion
of inflammatory cells to endothelial cells, which could
promote inflammatory reactions in atherosclerosis [29].
Furthermore, attenuated fibrinolytic activity by increased
PAI-1 levels is associated with the increased risk for
atherothrombosis and cardiovascular disease in diabetic
patients [30]. Given that AGEs could induce ICAM-1
and PAI-1 gene expressions in HUVECs via ROS gener-
ation through the interaction with RAGE [21, 31], block-
ade of the AGE-RAGE interaction by n-butanol extracts
Fig. 2 Effects of noni extracts on RAGE (a), ICAM-1 (b), and PAI-1 (c) mRNA levels in AGE-exposed HUVECs. HUVECs were treated with 100 μg/ml
AGE-BSA or non-glycated BSA in the presence or absence of 670 ng/ml n-butanol extracts of noni for 4 h. Then total RNAs were transcribed and
amplified by real-time PCR. Data were normalized by the intensity of β-actin (a) or 18S mRNA-derived signals (b and c) and then related to the
value obtained with non-glycated BSA treatment alone. a N = 4 per group. b and c N = 8 per group. * and **, p < 0.05 and p < 0.01 compared to
the value with AGEs alone, respectively
Fig. 3 Effects of noni extracts on THP-1 cell adhesion to AGE-exposed
HUVECs. HUVECs were treated with 100 μg/ml AGE-BSA or non-glycated
BSA in the presence or absence of 670 ng/ml n-butanol extracts of noni
for 24 h. Then HUVECs were incubated with BCECF-AM-labeled THP-1
cells for 4 h. Non-adherent THP-1 cells were removed. Fluorescent
intensities of the adherent THP-1 cells were measured. N= 6 per group.
**, p< 0.01 compared to the value with AGEs alone
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of noni may be a central mechanism by which they could
protect against AGE-induced endothelial cell injury, thus
becoming a therapeutic target for atherosclerotic cardio-
vascular disease. Iridoids are found in various types of
medicinal plants, including noni, have been reported to
block the inflammatory reactions in AGE-exposed mesan-
gial cells and kidneys of diabetic mice [32, 33]. It would be
interesting to examine whether iridoids could actually
inhibit the binding of AGEs to RAGE in vitro.
Limitations
Although the composition of noni fruits has been exten-
sively studied and there are a lot of data available on
how to analyze the bioactive compounds [15–17, 19],
the active substance has not been fully characterized in
the present study. Further experiments using high
performance liquid chromatography would be helpful to
address the issue.
In this study, freeze-dried flesh of Morinda citrifolia
was extracted first with 50% ethanol, and then with ethyl
acetate and n-butanol several times. The reason why the
native ethanol extracts were not included in this study
was that they were inactive; their binding affinity to
RAGE was less than one-sixth of those of n-butanol
extracts (data not shown). Furthermore, n-butanol
extracts alone did not affect superoxide generation or
inflammatory reactions in BSA-exposed HUVECs (Figs. 2
and 3). So it is unlikely that the solvents exerted toxic
effects on HUVECs. However, the relevance of n-butanol
extracts as a potential therapeutic agent in diabetic
vascular complications remains unclear.
We used freeze-dried samples after more than 10 years
of storage in the present experiments. However, just
after the collection during 2004–2006, the fruits were
freeze-dried and stored in dark place at 4 °C. Our previ-
ous and present studies have suggested that the butanol
extracts of freeze-dried and stored samples are bioactive
because they not only inhibited the binding of AGEs to
RAGE [17], but also suppressed the harmful effects of
AGEs on HUVECs. It would be interesting to compare
the bioactivity of fresh samples with that of stored sam-
ples in HUVECs.
In the present study, the effects of AGEs on ICAM-1
and PAI-1 mRNA levels were much stronger than on
RAGE mRNA levels. Although AGEs have been shown
to evoke the inflammatory reactions in HUVECs via
RAGE interaction [21, 31], the time-response curves of
gene expressions may differ.
Conclusions
The present study suggests that n-butanol extracts of
noni may inhibit inflammatory reactions in AGE-
exposed HUVECs through its anti-oxidative properties.
Since we have found that circulating levels of AGEs are
associated with vascular inflammation and endothelial
dysfunction in humans [34, 35], blockade by noni
extracts of the interaction of AGE with RAGE may be a
novel therapeutic strategy for atherosclerotic cardiovas-
cular disease.
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